Belén Garijo: Our appreciation to every shift colleague across our global network
“Arriving very late or finishing very early, shift work is never easy. I know the challenges from my time as a doctor in the hospital.
But the customers and patients of Merck Group depend upon our shift workers keeping the wheels turning 365 days a year. Across Life Science, Healthcare and Electronics, they carry much of this vital responsibility on their shoulders.
Before the holiday season break, it’s become a heartfelt tradition to recognize their dedication. My colleagues of the Executive Board and I were onsite at our company headquarters in Darmstadt, Germany late last night during the evening shift change. It´s a small token of our appreciation to every shift colleague across our global network. You make us all very proud.”
Source: /LinkedIn
Belén Garijo is the Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. She joined the company in 2011 as Chief Operating Officer of the Biopharma business, becoming President and CEO of Healthcare in 2015. In July 2020, Belén Garijo was appointed Vice Chairman of the Executive Board and Deputy CEO in addition to her role as CEO of the Healthcare business. She moved from Deputy CEO to CEO in May 2021.
Under her leadership, Healthcare at Merck KGaA, Darmstadt, Germany, has become a key player in the area of oncology, immunology and immuno-oncology, after the profound repositioning of the portfolio, the reorganization of R&D and the transformation of the commercial model. Before joining Merck, Belén Garijo served as the Senior Vice President of Global Operations Europe at Sanofi-Aventis and Global Integration Leader of Genzyme after its acquisition by Sanofi.
She previously held several local and global executive positions, both in R&D and commercial, at various companies at the forefront of the Healthcare sector. She started her career as a practicing physician at La Paz hospital in Madrid before moving to the pharmaceutical industry. She is a medical doctor, specialized in clinical pharmacology.
